xevinapant (Debio 1143)
NSCLC in combination with avelumab
Debio 1143 is a potent, orally available, inhibitor of IAPs (Inhibitor of Apoptosis Proteins) that displays immunomodulatory properties making it a natural candidate for combination with Immune Checkpoint Inhibitors. In addition, like other members of the class, Debio 1143 promotes apoptosis of cancer cells by mimicking the activity of the natural Second Mitochondrial-derived Activator of Caspases (SMAC). Through this dual mode of action, Debio 1143 is expected to improve cancer patient treatment outcomes in combination with immunotherapy, chemotherapy and/or radiotherapy respectively investigated in NSCLC, H&N cancer and Ovarian Cancer.
October 23, 2018
SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer
November 21, 2014
Debio 1143 in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC)…